1. Home
  2. UBCP vs RLYB Comparison

UBCP vs RLYB Comparison

Compare UBCP & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Bancorp Inc.

UBCP

United Bancorp Inc.

N/A

Current Price

$15.87

Market Cap

91.6M

Sector

Finance

ML Signal

N/A

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.24

Market Cap

92.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBCP
RLYB
Founded
1902
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.6M
92.9M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
UBCP
RLYB
Price
$15.87
$16.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.0K
39.3K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
5.73%
N/A
EPS Growth
5.51
N/A
EPS
0.33
N/A
Revenue
N/A
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.58
N/A
P/E Ratio
$48.08
N/A
Revenue Growth
N/A
43.00
52 Week Low
$12.47
$0.40
52 Week High
$17.34
$17.57

Technical Indicators

Market Signals
Indicator
UBCP
RLYB
Relative Strength Index (RSI) 52.46 55.59
Support Level $14.98 $15.60
Resistance Level $16.12 $16.50
Average True Range (ATR) 0.46 0.49
MACD 0.01 -0.01
Stochastic Oscillator 53.09 42.57

Price Performance

Historical Comparison
UBCP
RLYB

About UBCP United Bancorp Inc.

United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which include accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. The Company's primary deposit products are checking, savings, and term certificate accounts, and its primary lending products are residential mortgage, commercial, and installment loans. The bank also operates in Marshall County, West Virginia.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: